Which feature describes Ticagrelor?

Which feature describes Ticagrelor?

• A. Not a pro-drug, reversible
• B. Irreversible, pro-drug
• C. Only IV administration
• D. Only after PCI

Answer: (A)

Ticagrelor is a direct-acting, reversible P2Y12 receptor antagonist and is not a prodrug. This means it doesn’t require metabolic activation to exert its effect, and its platelet inhibition is not permanent—when the drug is stopped, platelets can regain function as new platelets enter circulation. The reversibility also provides a faster offset of antiplatelet effect compared with irreversible, prodrug agents, which is clinically relevant if urgent surgery or bleeding concerns arise. Ticagrelor is taken orally, not given by IV, and it is used in ACS management with or without PCI, not limited to after PCI. The other statements don’t fit because ticagrelor is neither irreversible nor a prodrug, and it isn’t restricted to post-PCI or to IV administration.

Ticagrelor is a direct-acting, reversible P2Y12 receptor antagonist and is not a prodrug. This means it doesn’t require metabolic activation to exert its effect, and its platelet inhibition is not permanent—when the drug is stopped, platelets can regain function as new platelets enter circulation. The reversibility also provides a faster offset of antiplatelet effect compared with irreversible, prodrug agents, which is clinically relevant if urgent surgery or bleeding concerns arise. Ticagrelor is taken orally, not given by IV, and it is used in ACS management with or without PCI, not limited to after PCI. The other statements don’t fit because ticagrelor is neither irreversible nor a prodrug, and it isn’t restricted to post-PCI or to IV administration.